Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEASIde: HS235 dose-ranging study in pulmonary arterial hypertension
2025-523010-89-00Phase 2Authorised
- Sponsor
- 35Pharma
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2 trial of HS235 in pulmonary arterial hypertension (PAH) (2 arms), sponsored by 35Pharma. Planned start Oct 2026; status: authorised.
02
Drugs
HS235
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2025-523010-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523010-89-00.